HMHA1 Polyclonal Antibody | Invitrogen PA5-44232 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

HMHA1 Polyclonal Antibody

catalog :

PA5-44232

quantity :

100 uL

price :

US 464.00

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

reactivity :

human

application :

western blot

product information

Product Type :

Antibody

Product Name :

HMHA1 Polyclonal Antibody

Catalog # :

PA5-44232

Quantity :

100 uL

Price :

US 464.00

Clonality :

Polyclonal

Purity :

Affinity Chromatography

Host :

Rabbit

Reactivity :

Human

Applications :

Western Blot: 1 ug/mL

Species :

Human

Isotype :

IgG

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domain which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Immunogen :

Synthetic peptide directed towards the N-terminal of human HMHA1 (aa 512-561).

Format :

Liquid

Applications w/Dilutions :

Western Blot: 1 ug/mL

Aliases :

6330406L22Rik; ARHGAP45; AW539505; Ha-1; histocompatibility (minor) HA-1; HLA-HA1; Hmha1; KIAA0223; mHag HA-1; Minor histocompatibility antigen HA-1; minor histocompatibility protein HA-1; minor histocompatibility protein HA-1; rho GTPase-activating protein 45; RGD1308662; Rho GTPase activating protein 45; rho GTPase-activating protein 45